Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

被引：0
作者：
Yang Yang
Qilong Liu
Lei Cao
Wei Sun
Xiaowei Gu
Bin Liu
Na Xiao
Fei Teng
Xiaoli Li
Meiji Chen
Weiguang Yu
Huanyi Lin
Guixing Xu
机构：
[1] Affiliated Hospital of Hebei University,Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology
[2] Sun Yat-Sen University,Department of Gastrointestinal Surgery, The First Affiliated Hospital
[3] Huazhong University of Science and Technology,Department of Anaesthesiology, The Central Hospital of Wuhan, Tongji Medical College
[4] Affiliated Hospital of Hebei University,Department of Head and Neck Surgery
[5] Affiliated Hospital of Hebei University,Central Laboratory
[6] Affiliated Hospital of Hebei University,Department of Radiotherapy
[7] Sun Yat-Sen University,Department of Pediatrics, The First Affiliated Hospital
[8] Sun Yat-Sen University,Department of Orthopaedics, The First Affiliated Hospital
[9] Sun Yat-Sen University,Department of Urinary Surgery, The First Affiliated Hospital
[10] Sun Yat-Sen University,Department of Neurosurgery, The First Affiliated Hospital
来源：
BMC Pulmonary Medicine | / 21卷
关键词：
Osimertinib; Afatinib; Non-small-cell lung cancer; Central nervous system; Metastases; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 249 条
  • [1] Soria JC(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 378 113-125
  • [2] Ohe Y(2016)Osimertinib: first global approval Drugs 76 263-273
  • [3] Vansteenkiste J(2017)Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component J Clin Oncol 35 1288-+
  • [4] Reungwetwattana T(2018)CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials Ann Oncol 29 687-693
  • [5] Chewaskulyong B(2018)Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated NSCLC J Thorac Oncol 13 E161-E163
  • [6] Lee KH(2016)Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Lancet Oncol 17 577-589
  • [7] Dechaphunkul A(2015)Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) JAMA Oncol 1 1051-1059
  • [8] Imamura F(2017)Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA Ann Oncol 28 784-790
  • [9] Nogami N(2013)A phase IB study of high-dose intermittent (HDI) afatinib in EGFR T790m mutation-positive non-small cell lung cancer patients with acquired resistance to reversible egfr tkis J Thorac Oncol 8 S893-S893
  • [10] Kurata T(2015)Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation Oncotarget 6 5832-5845
12345678910